Relation
ChAdOx1 nCoV-19 Animal Trials
- ChAdOx1 nCoV-19 is a viral vector vaccine which has been tested against small animals with varying success. T-Cell responses have been higher in pigs 42 days in rather than 14 days, and one dose of this vaccine elicits an antibody response.
- In chimpanzies, vaccines of ChAdOx1 MERS were given to prrevent MERS-CoV. The vaccine was safe, well tolerated, and chimpanizes showed an enhanced immune response to MERS-CoV within 1 months of vaccination.
0
1
Updated 2020-10-06
References
Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Tags
SARS-CoV-2 (COVID-19)
Biomedical engineering
Biomedical Sciences